Scientific ValidityEsketamine, also known as Spravato, has garnered substantial attention in the scientific community for its efficacy in treating treatment-resistant depression. Rigorous clinical trials and studies such as
this study here have reinforced its positive impact on individuals who have not responded adequately to conventional antidepressants.